Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sigma Healthcare Ltd ( (AU:SIG) ) has shared an announcement.
Sigma Healthcare has disclosed a change in director Danielle Di Pilla’s interests following the grant of 141,591 performance rights under the company’s 2025 Long Term Incentive Plan. The rights, issued for nil consideration as part of her employee incentive package and approved at the 2025 AGM, increase Di Pilla’s direct holdings to include both her substantial existing shareholding and the new long-term incentive rights, while her indirect interests via the Di Pilla Family Trust remain unchanged, underscoring Sigma’s continued use of equity-based remuneration to align executive interests with shareholder value.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.39 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
More about Sigma Healthcare Ltd
Sigma Healthcare Limited is an Australian healthcare company primarily involved in pharmaceutical wholesale and distribution, supporting pharmacies and healthcare providers across the country. The company operates within the broader healthcare and pharmaceuticals industry, with a focus on supplying medicines and related healthcare products to its network of customers.
Average Trading Volume: 15,600,081
Technical Sentiment Signal: Buy
Current Market Cap: A$33.53B
For an in-depth examination of SIG stock, go to TipRanks’ Overview page.